Goldman Sachs Reiterates Top Rating On Edwards Lifesciences (EW) Ahead of Upcoming Catalysts

Goldman Sachs reiterated its Conviction Buy List rating on Edwards Lifesciences (NYSE: EW), saying over the next six months there are several catalysts that could drive the shares higher.

Those catalysts, according to the firm include: "(1) US approval and launch of the SAPIEN transcatheter aortic valve (TAVI) in the nonsurgical population (PARTNER B); (2) cost effectiveness and quality of life data in the PARTNER A (surgical) group; (3) 3Q2011 results; and (4) the company’s annual analyst meeting in which management will provide 2012 guidance (December 9)."

The firm maintained their $91 price target, saying they see the current levels as an attractive entry point.

For more ratings news on Edwards Lifesciences click here and for the rating history of Edwards Lifesciences click here.

Shares of Edwards Lifesciences closed at $72.70 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Goldman Sachs Reinstates Etsy (ETSY) at Neutral
• Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
• Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform